Added to YB: 2025-03-13
Pitch date: 2025-03-12
CHRS [bullish]
Coherus Oncology, Inc.
+36.36%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Market Cap
$96.2M
Pitch Price
$0.99
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.12
P/E
1.95
EV/Sales
1.15
Sector
Biotechnology
Category
N/A
Coherus BioSciences Releases Q4 2024 Earnings Results, Udenyca Closing Soon
CHRS (earnings update): Q4 rev $54.1M, FY24 rev $267M (+4% YoY). Net income $28.5M vs -$237.9M in 2023. Udenyca sale closing Q1/Q2 2025, $250M cash post-sale. Loqtorzi sales +29% QoQ. Pipeline advancing. CEO hints at potential M&A. Headcount -30%. Possible acquisition target for Jazz Pharma.
Read full article (10 min)